Cure8 research brief
The paper identifies a metabolic pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to epithelial injury in ulcerative colitis and proposes quercetin as a candidate inhibitor—potentially pointing to new therapeutic strategies.
Researchers studying UC mechanisms, drug-discovery teams interested in metabolic or ferroptosis targets, and clinicians curious about emerging preclinical pathways in inflammatory bowel disease.
The authors used bioinformatics, cell models, and animal experiments to link HIF-1α-driven glycolysis and lactate production to increased protein lactylation and ferroptosis markers in colonic epithelial cells.
Reducing lactate or silencing HIF-1α lowered iron overload, lipid peroxidation, and reactive oxygen species; overexpressing HIF-1α had the opposite effect. The natural compound quercetin was identified by docking and shown in these models to bind HIF-1α and reduce the lactylation–ferroptosis axis, improving colitis measures in animals.
The study is preclinical: findings are mechanistic and hypothesis-generating rather than evidence that quercetin is an effective treatment in people with UC. Do not change medications or treatments based on this report.
This is an abstract of a basic-science journal article using bioinformatics, cell culture, and animal models. Results have not been validated in human clinical trials; quercetin’s safety, dosing, and efficacy for UC in people remain unestablished.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests a new mechanism—blocking HSP90-mediated necroptosis of intestinal epithelial cells—that may reduce inflammation and tissue damage in ulcerative colitis, which could guide early drug-discovery efforts.
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
